A Comprehensive Analysis of 2013 Dystrophinopathies in China: A Report From National Rare Disease Center

• Published in: Frontiers in neurology Vol. 11; p. 572006
• Main Authors: Tong, Yuan-Ren, Geng, Chang, Guan, Yu-Zhou, Zhao, Yan-Huan, Ren, Hai-Tao, Yao, Feng-Xia, Ling, Chao, Wang, Dan-Chen, Chen, Lin, Cui, Li-Ying, Zhang, Shu-Yang, Dai, Yi
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 30.09.2020
• Subjects: Becker muscular dystrophy; Duchenne muscular dystrophy; hospital-registry; mutation spectrum; Neurology; NRDRS; rare mutations
• ISSN: 1664-2295; 1664-2295
• DOI: 10.3389/fneur.2020.572006

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive neuromuscular disorders caused by mutations in DMD . A high-quality database of DMD/BMD is essential not only for clinical practice but also for fundamental research. Here, we aimed to build the largest Chinese national dystrophinopathy database using the National Rare Diseases Registry System of China. Peking Union Medical College Hospital (PUMCH) was the National Rare Diseases Center of China. This research involved 2013 patients with dystrophinopathies, whose diagnoses were confirmed; they were registered and followed up at PUMCH from March 2011 to December 2018. Family history, clinical signs, and treatment data were reported for patients with DMD and BMD at different rates. All six serum biochemical indexes could accurately distinguish between DMD and BMD patients. Copy number variations were the most frequent mutation type (79.2% in DMD and 84.3% in BMD), of which large deletions accounted for 88.4 and 88.6%, large duplications accounted for 11.6 and 11.4% in DMD and BMD, respectively. An exon deletion hotspot, located in exons 45–54, was observed in DMD, and intron 44 was the most frequent deletion starting point (26.5%). Duplication and single nucleotide variations appeared to be uniformly distributed among all exons. Eleven patients were identified to have ultrarare mutation types. Eleven other patients suffered from two separate mutations simultaneously, some of which may have taken place via dependent mechanisms. Thus, we have established the largest hospital-based Chinese dystrophinopathy database via the National Rare Diseases Registry System. This study provides valuable information for further diagnostic and therapeutic studies of dystrophinopathy.